Québec, Canada – March 30, 2026 – Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlights the results of its annual general and special meeting of shareholders held on March 27, 2026 (the “Meeting”) online via live webcast. The Company reported that shareholders voted on, and approved, the following proposals at the Meeting.

Election of Directors

Taking into account the proxies received, and the votes cast at the Meeting, the following individuals have been elected as directors of the Company until the next annual shareholders’ meeting: Dr. André P. Boulet, Luc Buisson, Pr. Louis Flamand, Kathryn J. Gregory, Pierre Labbé, Josh Muntner, Dr. Kira Sheinerman and Dennis Turpin.

Dr. André P. Boulet, Chairman and CEO mentioned: “We are pleased to welcome Josh, Kira and Luc to our board. Their extensive experience and strategic insight in financing strategy will be invaluable as we continue to execute on our growth strategy and create long-term value for our shareholders”.

Josh Muntner is a seasoned biopharmaceutical finance executive with over 25 years of experience as a Chief Financial Officer and investment banker. He has led more than 90 financings and strategic transactions, raising over $9 billion in capital. Mr. Muntner has held senior leadership roles across private and public life sciences companies, with responsibility for global finance, investor relations, and capital markets strategy. He holds a MBA from UCLA Anderson School of Management and a BFA from Carnegie Mellon University.

Dr. Kira Sheinerman is a Managing Director of Investment Banking at H.C. Wainwright and co-founder of DiamiR Biosciences. She brings deep expertise in healthcare fundraising, strategic advisory, and operations. Dr. Sheinerman has served on multiple boards and industry initiatives, including the Boyce Thompson Institute and the Alzheimer’s Association Business Consortium. She holds a PhD in Biomedical Sciences from Mount Sinai School of Medicine and an Honors MBA from Baruch College.

Luc Buisson is a Senior Strategic and Financial Advisor with over 35 years of experience in global investment banking and corporate finance. He previously served as Vice-Chair at HSBC across Canada and the Americas, advising governments, corporations, pension funds, and institutional investors on M&A, capital markets, and strategic transactions totaling more than $200 billion. Mr. Buisson is recognized for his sound judgment and ability to navigate complex stakeholder environments, providing pragmatic advice to boards and senior executives on mergers and acquisitions, capital structure, and transaction execution.

The Company also extends its sincere thanks to David Baker, Edouard Dahl and Luc Gregoire for their dedicated services and contributions to the Board over the past years.

Appointment of Auditors

Taking into account the proxies received, and the votes cast at the Meeting, MNP LLP has been appointed as the independent auditor of the Company for the current fiscal year ending July 31, 2026, and the directors of the Company have been authorized to determine its remuneration.

Option Plan Amendment

Under the TSX Venture Exchange (the “Exchange”) policies, the stock option plan of the Company (the “Option Plan”) is a “fixed up to 20%” plan, and any amendments must be approved by disinterested shareholders at a general meeting of the Company. The amendment aimed to increase the number of common shares in the capital of the Company (the “Shares”) reserved for issuance under the Option Plan, from 29,644,506 Shares on a pre‑consolidation basis (representing approximately 494,075 on a post-consolidation basis) to 553,146 Shares on a post‑consolidation basis, so that it would represent 20% of the issued and outstanding Shares. At the Meeting, disinterested shareholders approved the amendment to the Option Plan.

The full text of the Option Plan can be found in Schedule B of the Company’s management and information circular, a copy of which can be found on the Company’s SEDAR+ profile at www.sedarplus.ca. The Option Plan remains subject to the final approval of the Exchange.

About Devonian

Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune fibro-inflammatory disease with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription drugs for the treatment of fibro-inflammatory autoimmune diseases including but not limited to atopic dermatitis, radiodermatitis and ulcerative colitis.

Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare Group LP, focused on selling prescription pharmaceutical products in Canada, under licenses from brand name pharmaceutical companies.

Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Quebec, Canada where it owns a state-of-the art extraction facility. Devonian is traded publicly on the TSX Venture Exchange (the “Exchange”) (TSXV: GSD) and currently quoted on the OTCQB Venture Market (OTCQB: DVHGF).

For more information, please visit www.groupedevonian.com.

Cautionary Note Regarding Forward-Looking Statements

All statements, other than statements of historical fact, contained in this press release including, but not limited to the receipt of the final approval of the Exchange and those relating to  and generally, the above “About Devonian” paragraph, all of which essentially describes the Company’s outlook, constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws (collectively, “forward-looking statements”), and are based on expectations, estimates and projections as of the time of this press release. Such forward-looking statements may be identified by the use of words such as “intends”, “believes”, “expects”, or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, or “will” be taken, occur or be achieved.

Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Company disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.

Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT:
Devonian Health Group Inc.
Dr. André P. Boulet, PhD
Chairman & Chief Executive Officer
E-mail: investors@groupedevonian.com

The post Devonian Reports Results of its Annual General and Special Meeting of Shareholders appeared first on DEVONIAN HEALTH GROUP INC..

(all amounts are in Canadian dollars)

• Quarter ended January 31, 2026, net loss of $2.2 million dollars, ($0.81) per share
• Six months ended January 31, 2026, net loss of $3.8 million dollars, ($1.37) per share
• Cash as of January 31, 2026, $1.3 million; Company remains debt-free
• Reverse split of our common shares at ratio of sixty to one effected on January 22, 2026
• Thykamine™ radiodermatitis prevention pivotal clinical study as a first priority for the Company
• Company continues preclinical studies for Thykamine™ in MASH and Fibrosis, furthering the understanding of Thykamine™’s mechanism of action
• Thykamine™: A New Player in the Field of Anti-Inflammatory Drugs published in the peer reviewed journal, Biomedicines.

Québec, Canada – March 25, 2026 – Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlighted its financial and operating results for the three and six months ended January 31, 2026.

‘‘We are pleased with the continued momentum to execute on our priorities and readiness to advance our pipeline’’, said Dr. André P. Boulet, PhD, Chief Executive Officer and president of Devonian.

Corporate Highlights

Board Appointment and CFO

On November 26, 2025, the Company announced the appointment of Mr. Pierre Labbé, CPA as Board Director. Mr. Labbé was appointed Chair of the Audit Committee effective February 2, 2026.

On February 2, 2026, the Company announced the appointment of Mr. Dennis Turpin, CPA as Chief Financial Officer. Mr. Turpin remains on the Board of directors. He succeeded Ms. Viktoria Krasteva.

Strategic Update

Following the expiry of the Altius Healthcare LP (“Altius”) distribution agreements, the Company is transitioning toward a focused biopharmaceutical development strategy centered on Thykamine™. The Company is actively evaluating strategic alternatives for the Altius business while pursuing financing options to support its pipeline.

Steatohepatitis Associated with Metabolic Dysfunction

Metabolic dysfunction–associated steatotic liver disease progresses to metabolic dysfunction-associated steatohepatitis (“MASH”), which features inflammation, hepatocellular bloating, and subsequent worsening of fibrosis. If left untreated, MASH can progress to cirrhosis of the liver and hepatocellular carcinoma, liver failure, and death. Devonian recently completed a study investigating the effects of Thykamine™ on liver disease progression in the widely used STAM™ mouse model of MASH/fibrosis at SMC Laboratories in Japan1. In this model, diabetic mice were fed into a high-fat diet and rapidly developed fatty liver disease caused by inflammation and fat accumulation in the organ. Resmetirom, a drug approved by the U.S. FDA for the management of MASH, was used as a positive control at an oral dose of 3.0 mg/kg once daily for 3 weeks. Thykamine™ administered orally, at doses of 0.5 mg/kg, 5.0 mg/kg and 50.0 mg/kg, once daily for 3 weeks, suggest potential hepatoprotective effect preventing the progression of liver disease compared to the control (vehicle) group. The MASH study demonstrates that Thykamine™ has anti-inflammatory and anti-fibrotic effects with the potential to target the underlying pathology of the disease and thus halt the progression of the disease. Further studies are ongoing to highlight the potential of Thykamine™ to be used in the treatment of MASH.

Reference:

¹ In Vivo Efficacy Study of Thykamine^TM in STAM^TM Model of Metabolic dysfunction-associated steatohepatitis. SMC Laboratories Inc. Jan 2025.
Financial Highlights

Financial Highlights

Net Loss and Comprehensive Loss

For the three months ended January 31, 2026, the net loss and comprehensive loss was $2.2 million, $0.81 per share, compared to a net loss of $0.2 million, $0.09 per share, for the same period in 2025. This increase of $2 million in net loss and comprehensive loss is primarily due to lower distribution revenues resulting from the previously announced Dexlansoprazole expiry of its distribution agreement in April 2025. The lower distribution revenues reduced the comparative gross margin by $2.6 million partly offset by lower operating expenses of $0.2 million and lower income tax expenses of $0.4 million.

For the six-month periods ended January 31, 2026, the net loss and comprehensive loss was $3.8 million, $1.37 per share, compared to a net loss and comprehensive loss of $0.8 million, $0.36 per share, for the same period in 2025. This increase of $3 million in net loss and comprehensive loss is primarily due to lower distribution revenues resulting from the previously announced Dexlansoprazole expiry of its distribution agreement in April 2025. The lower distribution revenues reduced the comparative gross margin by $4.0 million, partially offset by lower operating expenses of $0.7 million and lower income tax expenses of $0.4 million net of lower interest income of $0.1 million.

In August 2025, Altius, which is ultimately owned by Devonian, was informed that the distribution agreement for Pantoprazole Magnesium would not be renewed after its expiry date of April 23, 2026.

Altius continues to sell Cleo-35® while Pantoprazole magnesium will end generating revenue post April 23, 2026. Distribution revenues will be driven by Cleo-35®, a product to treat hormonal acne in women.

Liquidity and Cash Flows

As of January 31, 2026, the Company had cash and cash equivalents totaling $1.3 million compared to $7 million as of July 31, 2025. For the six months ended January 31, 2026, the Company used $7.7 million of cash flows for its operating activities (composed of $3.2 million net loss after items not affecting cash and $4.5 million net change in non-cash working capital items), which were partially offset by the cash inflows of $2 million from two private placements completed during the same period. The Company is debt- free.

To consult the Interim Consolidated Financial Statements and the Management’s Discussion and Analysis of Financial Condition and Results of Operations for the three and the six months ended January 31, 2026 and 2025, please visit the following link: https://groupedevonian.com/investor-center/financial-reports/ or see the Company profile on SEDAR+.

About Thykamine™

Thykamine™, the first pharmaceutical product issued from Devonian’s SUPREX™ platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine™ have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with mild-to-moderate distal ulcerative colitis and in a large Phase II study in adult patients with mild-to-moderate Atopic Dermatitis. Both Thykamine™ and SUPREX™ platform are covered by patents issued in several North American, European, and Asian countries.

About Devonian

Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune fibroinflammatory disease with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription drugs for the treatment of fibroinflammatory autoimmune diseases including but not limited to atopic dermatitis, radiodermatitis and ulcerative colitis.
Devonian is involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian owns a commercialization unit, Altius, focused on selling prescription pharmaceutical products in Canada, under licenses from brand name pharmaceutical companies.

Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Quebec, Canada where it owns a state-of-the art extraction facility. Devonian is traded publicly on the TSX Venture Exchange (the “Exchange”) (TSXV: GSD) and currently quoted on the OTCQB Venture Market (OTCQB: DVHGF).

For more information, visit www.groupedevonian.com.

Cautionary Note Regarding Forward-Looking Statements

All statements, other than statements of historical fact, contained in this press release including, but not limited to those relating to the Company transitioning toward a focused biopharmaceutical development strategy centered on Thykamine™, the strategic alternatives for the Altius business, the financing options to support the Company’s pipeline, the revenues driven by Cleo-35®,the completion of radiodermatitis prevention pivotal clinical study and pre-clinical studies, the potential hepatoprotective effect preventing the progression of liver disease in MASH model, anti-inflammatory and anti-fibrotic effects with the potential to target the underlying pathology of the disease and thus halt the progression of the disease; and generally, the above “About Devonian” paragraph, all of which essentially describes the Company’s outlook, constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws (collectively, “forward-looking statements”), and are based on expectations, estimates and projections as of the time of this press release. Such forward-looking statements may be identified by the use of words such as “intends”, “believes”, “expects”, or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, or “will” be taken, occur or be achieved.

Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these  autionary statements and those made in our other filings with the applicable securities regulators of Canada. The Company disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.

Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT :
Devonian Health Group Inc.
Dennis Turpin, CPA
Chief Financial Officer
E-mail: investors@groupedevonian.com

The post Devonian Health Group Inc. Reports Financial and Operating Results of its Three and Six Months Ended January 31, 2026 appeared first on DEVONIAN HEALTH GROUP INC..

Quebec, Canada – February 19, 2026 — Devonian Health Group Inc. (“Devonian” or the Company) (TSXV: GSD; OTCQB: DVHGF) today announced positive results from a follow-up preclinical study evaluating Thykamine™ in a human metabolic-associated steatohepatitis (MASH) model using PhysioMimix® Liver-on-a-Chip platform. The study was conducted by CN Bio Innovations, Cambridge, UK.

Importantly, the study demonstrates that Thykamine™ exerts dose-dependent effects on key pathological hallmarks of MASH, including fibrosis and inflammation, in a physiologically relevant human liver system. These results represent a critical translational bridge between Devonian’s previously disclosed efficacy in the mouse STAM® MASH model and a predictive human microphysiological model.

Study Design and Dosing

Thykamine™ was evaluated at four low concentrations (0.025, 0.05, 0.1, and 0.2 mg/mL) over a 14-day treatment period in a dynamic, triple-cell liver model incorporating primary human hepatocytes, Kupffer cells, and hepatic stellate cells under continuous microfluidic flow to induce a MASH phenotype.

Elafibranor, a clinically advanced compound previously evaluated in MASH clinical trials3,4, was included as a reference positive control (20 uM), alongside a vehicle control.

Key Findings Demonstrating Impact on the MASH Phenotype

Disease-relevant reduction in fibrosis: Thykamine™ produced a clear, dose-dependent reduction in fibrosis-associated biomarkers, including pro-collagen and TIMP-1, with the strongest effects observed at 0.1 and 0.2 mg/mL. These markers are central to extracellular matrix deposition and fibrotic progression in MASH.

Suppression of collagen accumulation: Confocal imaging confirmed a significant decrease in Type I collagen deposition, indicating attenuation of one of the core structural features of fibrotic MASH. At higher doses, the magnitude of collagen reduction was greater than that observed with Elafibranor under identical experimental conditions.

Modulation of inflammatory signaling: Thykamine™ induced a dose-dependent reduction in pro-inflammatory cytokines IL-6 and IL-8 at later time points, reflecting an effect on inflammatory pathways that contribute to hepatocellular injury and disease progression in MASH.

Preservation of liver cell health: LDH levels remained low throughout the study, with no evidence of drug-induced liver injury. Observed changes in albumin production were not associated with cytotoxicity and will be further investigated.

“These findings show that Thykamine™ does more than modulate individual biomarkers—it impacts the core biological processes that define MASH, including fibrosis and inflammation,” said Dr. André P. Boulet, PhD, Chief Executive Officer of Devonian. “Together with our previously reported mouse STAM® data, this study strengthens the translational rationale for Thykamine™ as a potential disease-modifying therapeutic candidate” added Dr Boulet.

The PhysioMimix® Liver-on-a-Chip platform recapitulates key aspects of human MASH pathology by combining multi-cellular liver architecture with physiological flow. The consistent activity of Thykamine™ across in vivo and human organ-on-a-chip models supports its differentiated profile among emerging MASH therapeutics.

Devonian plans to advance additional preclinical studies to further characterize Thykamine™’s disease-modifying potential and support continued development in MASH and other fibrotic diseases.

About NAFLD/MASH1,2

Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease with a worldwide prevalence of 20-30%.  It is represented by fat accumulation in the liver, a condition that is commonly associated with features of the metabolic syndrome (MetS), such as obesity, type 2 diabetes, dyslipidemia, and hypertension.

NAFLD progresses to metabolic dysfunction-associated steatohepatitis (MASH), the hallmarks of which are inflammation, hepatocellular ballooning, and subsequent worsening fibrosis. Left untreated, MASH can ultimately progress to cirrhosis of the liver and hepatocellular carcinoma, liver failure and death.

The global Metabolic Dysfunction-Associated Steatohepatitis (MASH) treatment market is experiencing rapid growth, driven by rising rates of obesity, type 2 diabetes, and metabolic syndrome5.  According to DataM Intelligence6, the market was valued at $7.87 billion in 2024 and is projected to reach $31.76 billion by 2033, growing at a 17.7% CAGR from 2025 to 2033.

About Thykamine™

Thykamine™, the first pharmaceutical product issued from Devonian’s SUPREX™ platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine™ have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with mild-to-moderate distal ulcerative colitis and in a large Phase II study in adult patients with mild-to-moderate Atopic Dermatitis. Both Thykamine™ and SUPREX™ platform are covered by patents issued in several North American, European and Asian countries.

About CN Bio

CN Bio is on a mission to accelerate drug discovery. As a leading Organ-on-chip (OOC) company, the team is transforming how human-specific efficacy and safety data are generated. CN Bio’s human organ models deepen the understanding of disease mechanisms, help uncover new drug targets and enable development of novel, safe, and effective therapeutics. The Company’s portfolio of products and services offer deeper and more valuable insights into how drugs are predicted to perform in patients to greatly reduce risk, time and costs.

Based in Cambridge (UK), CN Bio leverages over a decade of experience and expertise in bringing single and multi-organ OOC based microphysiological systems (MPS) to the market. The Company’s ground-breaking benchtop PhysioMimix® Core System accurately mimics human physiology using advanced, predictive in vitro human organ models, relieving dependence on animals in line with regulatory change.

The power of PhysioMimix® technology has been harnessed by 16 leading pharmaceutical companies and is recognized by the US FDA, resulting in the first co-publication between a drug regulator and MPS provider, plus acceptance into the FDA’s ISTAND program.

PhysioMimix data has informed several regulatory filings, including a regulatory world first in 2023 when the Company supported a successful filing to initiate clinical testing for the treatment of metabolic liver disease.

To find out more about how CN Bio is pioneering faster, more accurate drug discovery, please visit: www.cn-bio.com or follow the company on LinkedIn @CN Bio.

About Devonian

Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune fibroinflammatory disease with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription drugs for the treatment of fibroinflammatory autoimmune diseases including but not limited to atopic dermatitis, radiodermatitis and ulcerative colitis.
Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare LP, focused on selling prescription pharmaceutical products in Canada, under licenses from brand name pharmaceutical companies.

Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Quebec, Canada where it owns a state-of-the art extraction facility. Devonian is traded publicly on the TSX Venture Exchange (the “Exchange”) (TSXV: GSD) and currently quoted on the OTCQB Venture Market (OTCQB: DVHGF).

For more information, visit www.groupedevonian.com.

References

1. Ekstedt M, Nasr P and Kechagias S. Natural History of NAFLD/NASH. Curr Hepatology Rep. 16:391-397, 2017.
2. Pierantonelli I. and Svegliati-Baroni G. Nonalcoholic Fatty Liver Disease: basic Pathogerenic Mechanisms in the Progression from NAFLD to NASH. Transplantation, 103(1): p e1-e13, 2019.
3. Ewsome PN and Loomba R. Therapeutic horizons in metabolic dysfunction–associated steatohepatitis. J Clin Invest.135(13):e186425; 2025.
4. GENFIT: Announces Results from Interim Analysis of RESOLVE-IT Phase 3 Trial of Elafibranor in Adults with NASH and Fibrosis, May 11, 2020
5. Jeffrey V. Lazarus JV, Brennan PN,Mark HE, et al. A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis.The Lancet Regional Health – Europe, 54:101320, 2025.
6. NASH/MASH Treatment Market Size, Share, Growth Insights and Forecast 2025-2033. DataM Intelligence, November 2025.

Cautionary Note Regarding Forward-Looking Statements

All statements, other than statements of historical fact, contained in this press release including, but not limited to those relating to the Common Shares consolidation; the anticipated post-consolidation trading price of the Common Shares; the potential impact of the consolidation on investor interest and liquidity; the ability to satisfy minimum price or other listing requirements of U.S and other stock exchanges; the impacts in perceived trading price following the consolidation; the ability of the Company to maintain compliance with regulatory requirements following the consolidation; and generally, the above “About Devonian” paragraph, all of which essentially describes the Company’s outlook, constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws (collectively, “forward-looking statements”), and are based on expectations, estimates and projections as of the time of this press release. Such forward-looking statements may be identified by the use of words such as “intends”, “believes”, “expects”, or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, or “will” be taken, occur or be achieved.

Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Company disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.

Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT:

Devonian Health Group Inc.
Dr. André P. Boulet
Chairman & Chief Executive Officer
Telephone: 1 (450) 979-2916
E-mail: investors@groupedevonian.com

The post Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects appeared first on DEVONIAN HEALTH GROUP INC..

Quebec, Canada – February 17, 2026 — Devonian Health Group Inc. (“Devonian” or the Company) (TSXV: GSD; OTCQB: DVHGF) today announced that a proprietary Thykamine™ fingerprint has been formally filed in two recent patent applications and is now a core component of the Company’s long-term intellectual property and patent strategy. This fingerprint will be systematically incorporated into all future Thykamine™-related patent filings.

The Thykamine™ fingerprint defines eight specific chemical components present in precise ratios, established using advanced HPLC-MS (High-Performance Liquid Chromatography–Mass Spectrometry) analytical methods. The HPLC-MS methodology has demonstrated high reproducibility across manufactured batches of Thykamine™, a result independently confirmed by NMR (Nuclear Magnetic Resonance) analysis, showing ≥98% confidence in batch-to-batch consistency.

Batch reproducibility was further validated through potency assays using a U-937 human cell-based model, demonstrating that every batch of Thykamine™ exhibits equivalent biological activity. These assays confirmed consistent inhibition of key inflammatory cytokines, including RANTES and MIP-1β, reinforcing the functional equivalence of each production batch. The potency assay is currently being validated for inclusion in the Chemistry, Manufacturing and Controls (CMC) section of Thykamine™ production.

Collectively, the HPLC-MS fingerprinting, NMR confirmation, and potency assays will form an integral part of Devonian’s CMC framework for Thykamine™ production, reinforcing regulatory preparedness and ensuring the level of manufacturing robustness required for pharmaceutical development.

Dr. André Boulet, Chief Executive Officer of Devonian, commented: “These analytical and biological methods clearly demonstrate the quality and consistency of Thykamine™ produced in every batch—not only from a chemical standpoint, but also as an active anti-inflammatory and anti-fibrotic pharmaceutical. This integrated approach provides strong confidence that patients will consistently receive a product of the same high quality, efficacy, and reliability.”

This milestone reinforces Devonian’s commitment to scientific rigor, intellectual property protection, and pharmaceutical-grade manufacturing as the Company continues to advance Thykamine™ through development.

About Thykamine™

Thykamine™, the first pharmaceutical product issued from Devonian’s SUPREX™ platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine™ have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with mild-to-moderate distal ulcerative colitis and in a large Phase II study in adult patients with mild-to-moderate Atopic Dermatitis. Both Thykamine™ and SUPREX™ platform are covered by patents issued in several North American, European and Asian countries.

About Devonian

Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune fibroinflammatory disease with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription drugs for the treatment of fibroinflammatory autoimmune diseases including but not limited to atopic dermatitis, radiodermatitis and ulcerative colitis.
Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare LP, focused on selling prescription pharmaceutical products in Canada, under licenses from brand name pharmaceutical companies.

Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Quebec, Canada where it owns a state-of-the art extraction facility. Devonian is traded publicly on the TSX Venture Exchange (the “Exchange”) (TSXV: GSD) and currently quoted on the OTCQB Venture Market (OTCQB: DVHGF).

For more information, visit www.groupedevonian.com.

Cautionary Note Regarding Forward-Looking Statements

All statements, other than statements of historical fact, contained in this press release including, but not limited to those relating to the Common Shares consolidation; the anticipated post-consolidation trading price of the Common Shares; the potential impact of the consolidation on investor interest and liquidity; the ability to satisfy minimum price or other listing requirements of U.S and other stock exchanges; the impacts in perceived trading price following the consolidation; the ability of the Company to maintain compliance with regulatory requirements following the consolidation; and generally, the above “About Devonian” paragraph, all of which essentially describes the Company’s outlook, constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws (collectively, “forward-looking statements”), and are based on expectations, estimates and projections as of the time of this press release. Such forward-looking statements may be identified by the use of words such as “intends”, “believes”, “expects”, or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, or “will” be taken, occur or be achieved.

Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Company disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.

Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT:

Devonian Health Group Inc.
Dr. André P. Boulet, PhD
Chairman & Chief Executive Officer
Telephone: 1 (450) 979-2916

E-mail: investors@groupedevonian.com

The post Devonian Advances Thykamine™ Patent Strategy with Proprietary Fingerprint and Robust Manufacturing Controls appeared first on DEVONIAN HEALTH GROUP INC..

Gene expression analysis from the STAM mouse model attributes Thykamine™ with dose-dependent anti-MASH, anti-inflammatory and anti-fibrosis molecular effects in liver.

QUÉBEC, Quebec, February 12, 2026 – Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to fibroinflammatory diseases, today announced additional preclinical results from its previously reported STAMTM mouse model in vivo study of metabolic dysfunction–associated steatohepatitis (MASH). These new data provide gene expression evidence supporting the anti-MASH, anti-inflammatory and anti-fibrotic effects of Thykamine™ observed in the liver.

As previously reported, the STAM™ mouse model study demonstrated that orally administered Thykamine™, at doses of 0.5 mg/kg, 5.0 mg/kg and 50.0 mg/kg once daily for three weeks, significantly reduced liver disease progression, inflammation and fibrosis. The gene expression results announced today further characterize the molecular mechanisms underlying these effects.

The study evaluated the impact of Thykamine™ on the expression of 29 genes associated with liver fibrosis and inflammation, including 13 fibrosis-related genes, 5 inflammation-related genes, and 11 genes involved in both inflammation and fibrosis pathways. At the maximum tested dose, Thykamine™ treatment resulted in marked down-regulation of multiple genes central to MASH pathophysiology, with several demonstrating reductions approaching or exceeding 80–90% relative to placebo-treated animals.

Fibrosis-related genes significantly modulated by Thykamine™ included CCN1, CCN2, COL1A1, COL1A2, COL5A2, JAG1, MMP2, MMP13, SERPINE1, SERPINE2, SNAI1, and TGFBR1, supporting the previously observed decreases in collagen deposition, α-SMA expression and fibrosis progression.

Thykamine™ treatment also resulted in significant down-regulation of inflammation-related genes, including CCL2, CCR2, IFNG, and MMO8, as well as genes involved in both inflammatory and fibrotic remodeling such as COL3A1, COL6A1, FN1, TGFB1, TIMP1, MMP14, TNF, IL10, and TLR4.

A dose-dependent response was observed across gene categories, consistent with a pharmacologically driven effect. In addition, gene expression analysis revealed key differences between the caudal and lateral liver lobes, indicating regional variation in Thykamine™’s molecular activity within the diseased liver.

Gene expression analysis (PCR) was performed by Dr. Louis Flamand, PhD, MBA, Department of Microbiology, Infectious Disease and Immunology, Faculty of Medicine, Université Laval, Quebec City, Quebec, Canada. Statistical analyses were conducted by Dr. John Sampalis, PhD, Department of Surgery, McGill University, Montreal, Quebec, Canada.

“We are delighted to share these gene expression results, which provide important molecular confirmation of the anti-inflammatory and anti-fibrotic effects of Thykamine™ observed in the STAM™ MASH model,” said Dr. Andre P. Boulet, PhD, Chief Executive Officer of the Company. “The data demonstrate that Thykamine™ modulates multiple genes involved in fibrosis and inflammation, reinforcing its potential to target underlying disease pathology and prevent progression of MASH.”

“This study further adds to the growing body of evidence supporting Thykamine™’s multi-targeting mode of action,” said Dr André P. Boulet PhD, CEO of the Company. “By demonstrating consistent effects at both the histological and molecular levels, these results strengthen Thykamine™’s positioning across a broad array of inflammatory diseases, now including hepatic conditions alongside dermatology and Inflammatory Bowel Dises.”

The complete gene expression results will be included in the planned scientific publication of the STAM™ MASH preclinical study.

About NAFLD/MASH1,2

Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease with a worldwide prevalence of 20-30%.  It is represented by fat accumulation in the liver, a condition that is commonly associated with features of the metabolic syndrome (MetS), such as obesity, type 2 diabetes, dyslipidemia, and hypertension.

NAFLD progresses to metabolic dysfunction-associated steatohepatitis (MASH), the hallmarks of which are inflammation, hepatocellular ballooning, and subsequent worsening fibrosis. Left untreated, MASH can ultimately progress to cirrhosis of the liver and hepatocellular carcinoma, liver failure and death.

The global Metabolic Dysfunction-Associated Steatohepatitis (MASH) treatment market is experiencing rapid growth, driven by rising rates of obesity, type 2 diabetes, and metabolic syndrome3.  According to DataM Intelligence4, the market was valued at $7.87 billion in 2024 and is projected to reach $31.76 billion by 2033, growing at a 17.7% CAGR from 2025 to 2033.

About Thykamine™

Thykamine™, the first pharmaceutical product issued from Devonian’s SUPREX™ platform, is a highly innovative product for the prevention and treatment of health conditions related to fibroinflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine™ have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with mild-to-moderate distal ulcerative colitis and in a large Phase II study in adult patients with mild-to-moderate Atopic Dermatitis. Both Thykamine™ and SUPREX™ platform are covered by patents issued in several North American, European and Asian countries.

About Devonian

Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune fibroinflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription drugs for the treatment of inflammatory autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a U.S. Food and Drug Administration set of regulatory guidelines favoring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines.
Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare LP., focused on selling prescription pharmaceutical products in Canada, under license from brand name pharmaceutical companies.

Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility. Devonian is traded publicly on the TSX Venture Exchange (the “Exchange”) (TSXV: GSD) and on OTCQB exchange (OTCQB: DVHGF).

For more information, visit www.groupedevonian.com.

References

1. Ekstedt M, Nasr P and Kechagias S. Natural History of NAFLD/NASH. Curr Hepatology Rep. 16:391-397, 2017.
2. Pierantonelli I. and Svegliati-Baroni G. Nonalcoholic Fatty Liver Disease: basic Pathogerenic Mechanisms in the Progression from NAFLD to NASH. Transplantation, 103(1): p e1-e13, 2019.
3. Jeffrey V. Lazarus JV,  Brennan PN,Mark HE, et al. A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis.The Lancet Regional Health – Europe, 54:101320, 2025.
4. NASH/MASH Treatment Market Size, Share, Growth Insights and Forecast 2025-2033. DataM Intelligence, November 2025.

Cautionary Note Regarding Forward-Looking Statements

All statements, other than statements of historical fact, contained in this press release including, but not limited to those relating to the Common Shares consolidation; the anticipated post-consolidation trading price of the Common Shares; the potential impact of the consolidation on investor interest and liquidity; the ability to satisfy minimum price or other listing requirements of U.S and other stock exchanges; the impacts in perceived trading price following the consolidation; the ability of the Company to maintain compliance with regulatory requirements following the consolidation; and generally, the above “About Devonian” paragraph, all of which essentially describes the Company’s outlook, constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws (collectively, “forward-looking statements”), and are based on expectations, estimates and projections as of the time of this press release. Such forward-looking statements may be identified by the use of words such as “intends”, “believes”, “expects”, or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, or “will” be taken, occur or be achieved.

Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Company disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.

Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT:

Devonian Health Group Inc.
Dr. André P. Boulet, PhD
Chairman & Chief Executive Officer
Telephone: 450-979-2916

The post DEVONIAN REPORTS ADDITIONAL MOLECULAR DATA FROM MASH LIVER STUDY appeared first on DEVONIAN HEALTH GROUP INC..

• Positive results from the Bleomycin Pulmonary Fibrosis mouse model in vivo study attributing Thykamine™ with anti-fibrotic effects in lungs
• Compelling results compared to Pirfenidone, a drug used to treat idiopathic pulmonary fibrosis.
  

QUÉBEC, Quebec, February 10, 2026 – Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to fibroinflammatory diseases, today announced a potential expanded therapeutic application for Thykamine™, with compelling preclinical data results demonstrating proof of concept efficacy in a well-established animal model of pulmonary fibrosis.

The study investigated the effects of Thykamine™ in bleomycin-induced pulmonary fibrosis (IPF) mouse model, a widely used preclinical tool for studying idiopathic pulmonary fibrosis (IPF) pathophysiology and testing antifibrotic therapies. Pulmonary fibrosis was induced in mice using intranasal bleomycin, a gold-standard and clinically relevant model that closely mirrors key pathological features of human idiopathic pulmonary fibrosis.

Thykamine™ was administered orally at doses of 0.05, 0.1, 0.25, 0.5, and 1 mg/kg, and benchmarked against pirfenidone dosed at 220 mg/kg. Over a 21-day period, animals were monitored for body weight and survival, followed by comprehensive lung assessment. Fibrotic burden was evaluated through lung weight, collagen content, fibrosis-related gene expression, and histopathological scoring.

In this bleomycin-induced pulmonary fibrosis model, Thykamine™ demonstrated statistically significant antifibrotic activity, while pirfenidone did not reach statistical significance in physiological endpoints. Treatment with Thykamine™ at 0.5 mg/kg significantly reduced lung wet weight and lung tissue index compared with the bleomycin/vehicle group.

Bleomycin exposure led to marked increases in fibrosis (Ashcroft score) and inflammation compared with sham controls. Thykamine™ treatment significantly reversed these pathological changes, reducing both fibrosis and inflammation scores and indicating meaningful improvement in lung morphology.

Consistent with its effects on lung pathology, Thykamine™ at 0.5 mg/kg produced a statistically significant downregulation of key fibrosis- and inflammation-associated genes, including Fn1 (fibronectin), Col1a1, Col3a1, Col6a1, and Col6a3 (collagen isoforms involved in extracellular matrix deposition), Birc5, and the chemokines Ccl2 and Cxcl2 (inflammatory cell recruitment). In parallel, Thykamine™ significantly increased Mmp9, a matrix metalloproteinase associated with extracellular matrix turnover, while reducing Mmp13, a collagenase often linked to progressive tissue injury and inflammation. Together, this gene expression profile is consistent with controlled matrix remodeling and attenuation of fibrotic progression.

This well-validated model delivers a strong, dose-responsive demonstration of antifibrotic efficacy across multiple translational endpoints, clearly positioning Thykamine™ as a differentiated, next-generation therapeutic candidate in pulmonary fibrosis. The Company plans to present data in an upcoming scientific publication.

“These results represent a major inflection point for Thykamine™,” said Dr. Andre P. Boulet, PhD, Chief Executive Officer. “The pulmonary fibrosis data not only confirm and extend the antifibrotic effects we previously observed in mouse MASH model, but also significantly broaden Thykamine™’s mechanism of action. By combining potent anti-inflammatory and anti-fibrotic activity at low doses, Thykamine™ demonstrates clear potential to address the underlying biology of fibro-inflammatory diseases and to serve as a scalable, multi-indication platform with disease-modifying potential.”

About Pulmonary Fibrosis^1,2,3,4,5

Pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF), is a chronic, progressive, and ultimately fatal interstitial lung disease characterized by irreversible scarring of lung tissue, leading to declining respiratory function and premature mortality. IPF carries a poor prognosis, with median survival estimated at approximately three to five years from diagnosis, highlighting the urgent need for more effective therapies.
Epidemiological studies and recent systematic reviews indicate that the incidence and prevalence of IPF are increasing worldwide, driven in part by aging populations and improved diagnostic awareness. Current estimates suggest an incidence of several cases per 100,000 persons per year, with prevalence rising substantially in older age groups, placing a growing burden on patients and healthcare systems.

Despite the availability of approved antifibrotic therapies, treatment options remain limited and primarily slow disease progression without reversing fibrosis and are often associated with tolerability challenges. As a result, pulmonary fibrosis represents a significant unmet medical need and a rapidly expanding therapeutic market, reinforcing the importance of developing disease-modifying therapies that can more effectively target the underlying fibro-inflammatory drivers of disease.

About Thykamine™

Thykamine™, the first pharmaceutical product issued from Devonian’s SUPREX™ platform, is a highly innovative product for the prevention and treatment of health conditions related to fibroinflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine™ have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with mild-to-moderate distal ulcerative colitis and in a large Phase II study in adult patients with mild-to-moderate Atopic Dermatitis. Both Thykamine™ and SUPREX™ platform are covered by patents issued in several North American, European and Asian countries.

About Devonian

Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune fibroinflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription drugs for the treatment of inflammatory autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a U.S. Food and Drug Administration set of regulatory guidelines favoring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines.

Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare LP., focused on selling prescription pharmaceutical products in Canada, under license from brand name pharmaceutical companies.

Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility. Devonian is traded publicly on the TSX Venture Exchange (the “Exchange”) (TSXV: GSD) and on OTCQB exchange (OTCQB: DVHGF).
For more information, visit www.groupedevonian.com.

References

• Golchin N, Patel A, Scheuring J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis: a systematic literature review and meta-analysis. BMC Pulmonary Medicine. 25:378, 2025.
• Lederer DJ, and Martinez FJ. Idiopathic Pulmonary Fibrosis. N ENGL J MED, 378: 1811-23, 2018
• Chang A, Ry PM and Raghu G. Idiopathic pulmonary fibrosis: aligning murine models to clinical trials in humans. The Lancet Respiratory Medicine 11: P953-955, 2023.
• Marinescu D, Wong AW. Epidemiology of idiopathic pulmonary fibrosis: opportunities and hurdles for population-level studies of rare disease. Thorax 2024;79:603-604.
• Maher TM. Interstitial Lung Disease, A Review. JAMA, 331(19): 1655-1665, 2024.

Cautionary Note Regarding Forward-Looking Statements

All statements, other than statements of historical fact, contained in this press release including, but not limited to those relating to the Common Shares consolidation; the anticipated post-consolidation trading price of the Common Shares; the potential impact of the consolidation on investor interest and liquidity; the ability to satisfy minimum price or other listing requirements of U.S and other stock exchanges; the impacts in perceived trading price following the consolidation; the ability of the Company to maintain compliance with regulatory requirements following the consolidation; and generally, the above “About Devonian” paragraph, all of which essentially describes the Company’s outlook, constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws (collectively, “forward-looking statements”), and are based on expectations, estimates and projections as of the time of this press release. Such forward-looking statements may be identified by the use of words such as “intends”, “believes”, “expects”, or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, or “will” be taken, occur or be achieved.

Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Company disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.

Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT:

Devonian Health Group Inc.
Dr. André Boulet, PhD
Chairman & chief Executive Officer
Telephone: 450-979-2916
E-mail: investors@groupedevonian.com

The post DEVONIAN REPORTS POSITIVE RESULTS IN PULMONARY FIBROSIS STUDY appeared first on DEVONIAN HEALTH GROUP INC..

Mr. Turpin is a seasoned professional executive and chartered professional accountant (CPA) with significant experience in finance, capital markets transactions, business development as well as mergers and acquisitions, over 25 years of which have been in the biopharmaceutical industry.

“I am pleased to welcome Dennis and confident that he will help strengthen our management approach, diversify our perspectives, enhance our collective expertise, and help guide the development of Devonian.” said Dr. André P. Boulet, PhD, Chief Executive Officer.

Mr. Turpin will replace Viktoria Krasteva, who will remain with the Company and assist ensuring a smooth transition until February 27, 2026. The Board would like to thank Ms. Krasteva for her contributions to the Company and wishes her well in her future endeavors.

A total of 25,000 stock options were granted to Mr. Turpin.  These options are vesting immediately and are exercisable at a price of $11.50, for a period of 10 years following the grant date.

Options Grant Updates

The Company also wishes to correct the press release issued on December 19, 2025, regarding the granting of 2,948,056 stock options to directors and a consultant of the Company, as well as the additional grants of 385,950 stock options to employees and 100,000 stock options to a research and development consultant. Pursuant to the terms of the stock option plan, the exercise price of stock options may not be set below the market price of the common shares at the close of trading on the exchange on the trading day immediately preceding the grant date. Accordingly, the exercise price previously disclosed as $0.18 has been corrected to $0.19, being the applicable market price at the close of trading on the exchange on the trading day immediately preceding the grant date. All other terms of the stock option grants remain unchanged. Further to the share consolidation completed by the Company on January 22, 2026, on the basis of one post‑consolidation common share for every 60 pre‑consolidation common shares, the stock options described above have been automatically adjusted in accordance with the terms of the Company’s stock option plan. As a result, each block of 60 pre‑consolidation options now represents one post‑consolidation option, and the corrected exercise price of $0.19 per share has been adjusted to $11.40 per share on a post‑consolidation basis. The number of options has been rounded down to the next lowest whole in order to allow the holder to purchase only a whole number of common shares upon exercise.

About Devonian

Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune fibroinflammatory disease with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription drugs for the treatment of fibroinflammatory autoimmune diseases including but not limited to atopic dermatitis, radiodermatitis and ulcerative colitis.

Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare LP, focused on selling prescription pharmaceutical products in Canada, under licenses from brand name pharmaceutical companies.

Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Quebec, Canada where it owns a state-of-the art extraction facility. Devonian is traded publicly on the TSX Venture Exchange (the “Exchange”) (TSXV: GSD) and currently quoted on the OTCQB Venture Market (OTCQB: DVHGF).

For more information, visit www.groupedevonian.com.

Cautionary Note Regarding Forward-Looking Statements

All statements, other than statements of historical fact, contained in this press release including, the above “About Devonian” paragraph, all of which essentially describes the Company’s outlook, constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws (collectively, “forward-looking statements”), and are based on expectations, estimates and projections as of the time of this press release. Such forward-looking statements may be identified by the use of words such as “intends”, “believes”, “expects”, or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, or “will” be taken, occur or be achieved.

Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Company disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.

Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT:
Devonian Health Group Inc.
Dr. André P. Boulet, PhD
Chairman & Chief Executive Officer
Telephone: 450-979-2916
E-mail: investors@groupedevonian.com

The post Devonian appoints Dennis Turpin as chief financial officer and provides updates on stock options grant appeared first on DEVONIAN HEALTH GROUP INC..

The Company believes that the increase to the trading price of the Common Shares from effecting the consolidation could potentially, and principally (i) broaden the pool of investors that may consider investing or be able to invest in the Company, and (ii) enable the Company to satisfy certain minimum trading price requirements of U.S. and other stock exchanges for a potential listing of the Common Shares.

The Consolidation Ratio was determined by the Company’s board of directors and the officers of the Company in accordance with the parameters authorized by the Company’s shareholders at the Company’s annual and special meeting of the shareholders held on March 20, 2025. The consolidation is subject to final acceptance of the TSX Venture Exchange (the “TSXV”). The Company intends to complete the consolidation at the open of market on or around January 22, 2026 and the Common Shares are expected to commence trading on the TSXV on a post‑consolidation basis beginning at the open of markets on or around January 22, 2026, under the existing name and symbol “GSD”. On the OTCQB Venture Market, the Company’s trading symbol will also remain unchanged, although a “D” will be temporarily appended as the fifth character of the trading symbol for 20 business days starting the effective date of the consolidation. Following the consolidation, the new CUSIP number for the Common Shares will be 251834883 and the new ISIN number will be CA2518348834.

The Company currently has 165 943 512 Common Shares issued and outstanding and upon completion of the consolidation, the Company expects to have approximately 2 765 725 Common Shares issued and outstanding, subject to any issuances prior to the consolidation and rounding for any fractional shares. No fractional shares will be issued as a result of the consolidation and the number of post-consolidation shares to be received by each shareholder will be rounded to the nearest whole Common Share that such holder would otherwise be entitled to receive upon the implementation of the share consolidation.

Holders of Common Shares who hold uncertificated shares (that is shares held in book‑entry form and not represented by a physical share certificate), either as registered holders or beneficial owners, will have their existing book‑entry account(s) electronically adjusted by the Company’s transfer agent or, for beneficial shareholders, by their brokerage firm, banks, trusts or other nominees that hold in street name for their benefit. Such holders do not need to take any additional actions to exchange their pre‑consolidation Common Shares for post‑consolidation Common Shares. If you hold your Common Shares with such brokerage firm, bank, trust or other nominee, and if you have questions in this regard, you are encouraged to contact your nominee.

Registered shareholders holding share certificates will be mailed a letter of transmittal advising of the share consolidation and instructing them to surrender their share certificates representing pre‑consolidation Common Shares for replacement certificates or a direct registration advice representing their post‑consolidation Common Shares. Following the effective date of the consolidation, and until surrendered for exchange, each share certificate formerly representing pre‑consolidation Common Shares will be deemed to represent the number of whole post‑consolidation Common Shares to which the holder is entitled as a result of the consolidation.

About Devonian

Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune fibroinflammatory disease with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription drugs for the treatment of fibroinflammatory autoimmune diseases including but not limited to atopic dermatitis, radiodermatitis and ulcerative colitis.

Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare LP, focused on selling prescription pharmaceutical products in Canada, under licenses from brand name pharmaceutical companies.

Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Quebec, Canada where it owns a state-of-the art extraction facility. Devonian is traded publicly on the TSX Venture Exchange (the “Exchange”) (TSXV: GSD) and currently quoted on the OTCQB Venture Market (OTCQB: DVHGF).

For more information, visit www.groupedevonian.com.

Cautionary Note Regarding Forward-Looking Statements

All statements, other than statements of historical fact, contained in this press release including, but not limited to those relating to the anticipated effects and timing of the proposed consolidation; the expected range of the consolidation ratio; the anticipated post-consolidation trading price of the Common Shares; the potential impact of the consolidation on investor interest and liquidity; the ability to satisfy minimum price or other listing requirements of U.S and other stock exchanges; the expected number of Common Shares outstanding following completion of the consolidation; the impacts in perceived trading price following the consolidation; the final approval from the TSXV; the ability of the Company to maintain compliance with regulatory requirements following the consolidation; and generally, the above “About Devonian” paragraph, all of which essentially describes the Company’s outlook, constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws (collectively, “forward-looking statements”), and are based on expectations, estimates and projections as of the time of this press release. Such forward-looking statements may be identified by the use of words such as “intends”, “believes”, “expects”, or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, or “will” be taken, occur or be achieved.

Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Company disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.

Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT:
Devonian Health Group Inc.
Dr. André Boulet, PhD
Chairman & chief Executive Officer
Telephone: 450-979-2916
E-mail: investors@groupedevonian.com

The post Devonian announces share consolidation in further preparation for potential U.S. listing appeared first on DEVONIAN HEALTH GROUP INC..